Clinical trials: Moderate to Severe Dry Eye
Sjögren, Sjogren Disease
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.
- Conditions
- Sjögren, Sjogren Disease, Sjogren's Syndrome
- Trial name
- NCT07041099
- Testing
- CLN-978
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 36 people
- Sponsor
- Cullinan Therapeutics Inc.
Dry Eye, Dry Eye Disease (DED)
A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.
The purpose of this randomized, controlled, multicenter study is to evaluate the safety and efficacy of TTAX03 in participants with mild to moderate DED. The primary question it aims to answer is if TTAX03 is safe.
- Conditions
- Dry Eye, Dry Eye Disease (DED), Dry Eye Disease With Severe Keratitis
- Trial name
- NCT06780306
- Testing
- TTAX03
- Where
- 9 sites in United States
- Volunteers
- 74 people
- Sponsor
- BioTissue Holdings, Inc
Dry Eye Syndromes
Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease
This study will evaluate a new ophthalmic formulation of cyclosporine (Restasis® X) in patients with moderate to severe dry eye disease in two stages. Up to 3 doses will be studied in Stage 2 based on results from Stage 1.
- Trial name
- NCT02013791
- Testing
- Vehicle, Cyclosporine New Ophthalmic Formulation
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Allergan
Dry Eye Disease
HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)
The purpose of this study is to determine whether SYL1001 ophthalmic solution is safe and effective in the treatment of signs and symptoms of Dry Eye Disease.
- Trial name
- NCT03108664
- Testing
- SYL1001 ophthalmic solution, Vehicle opthalmic solution
- Where
- 40 sites in Estonia, Germany and 4 more
- Volunteers
- 330 people
- Sponsor
- Sylentis, S.A.
Keratoconjunctivitis Sicca
Trial of CF101 to Treat Patients With Dry Eye Disease
Eligible patients with dry eye will be treated with CF101 or placebo twice daily for 24 weeks. Disease activity will be assessed using evaluations of ocular surface integrity, tear production, and patient symptoms.
- Trial name
- NCT01235234
- Testing
- CF101
- Where
- Israel
- Volunteers
- 236 people
- Sponsor
- Can-Fite BioPharma
Moderate to Severe Dry Eye
A Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients
This study is a multi-site, unmasked PMS Study. The purpose of the study is to evaluate the physical effects of Systane Lubricant Eye Drops.
- Trial name
- NCT01311609
- Testing
- Systane
- Volunteers
- 300 people
- Sponsor
- Alcon Research
Dry Eye Syndromes
Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome
The main purpose of this study is to establish whether RP101 can reduce symptoms of dry eye syndrome in post-menopausal women.
- Trial name
- NCT03821415
- Testing
- RP101
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 104 people
- Sponsor
- Redwood Pharma AB
Dry Eye
Evaluation of the Efficacy and Safety of DM05 Versus Optive™ on the Treatment of Moderate to Severe Ocular Dryness
This study is a multicentric, comparative, randomized, investigator-blinded, in parallel groups study to demonstrate the non-inferiority of DM05 in comparison with Optive™, in terms of cornea and conjunctiva staining (Oxford…
- Trial name
- NCT03517748
- Testing
- DM05 eye drops, Optive™ eye drops
- Volunteers
- 80 people
- Sponsor
- Horus Pharma
Dry Eye Syndrome
Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.
The objective is to demonstrate the non-inferiority of T2769 compared to Hylo-Forte® in terms of the change from baseline (D1) in total ocular surface staining score assessed on Oxford 0-15 scale, in the study eye at the D36…
- Trial name
- NCT06375499
- Testing
- T2769, Hylo-Forte®
- Where
- 4 sites in Czechia, Hungary
- Volunteers
- 74 people
- Sponsor
- Laboratoires Thea
Sjögren Syndrome
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome.
- Trial name
- LOUiSSe (NCT04035668)
- Testing
- Remibrutinib
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease (DED)
Phase 3 Study of EBI-005 in Dry Eye Disease
This is a phase III double-masked, randomized, controlled study evaluating the efficacy of EBI-005 as compared to vehicle given as a topical ophthalmic solution in each eye to subjects with moderate to severe DED three times…
- Trial name
- EBI-005 (NCT01998802)
- Testing
- Active Comparator EBI-005
- Where
- 45 sites in United States
- Volunteers
- 670 people
- Sponsor
- Eleven Biotherapeutics
Moderate to Severe Dry Eye Syndrome
Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome
A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome
- Trial name
- NCT00814515
- Testing
- NOVA22007 (Ciclosporin 0.1%), NOVA22007
- Where
- France
- Volunteers
- 482 people
- Sponsor
- Santen SAS
Dry Eye Syndromes
Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome
Comparison of the efficacy and safety of T2750 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome
- Trial name
- NCT01568593
- Testing
- T2750, Vismed
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Laboratoires Thea
Dry Eye
Study of OT202 in Treating Moderate to Severe Dry Eye
This is a phase II study to explore the optimal dosage of OT202 in treating dry eye.
- Trial name
- NCT06435182
- Testing
- OT202 conc 0.5%, OT202 conc 0.1%
- Where
- 10 sites in China
- Volunteers
- 213 people
- Sponsor
- Ocumension Therapeutics (Shanghai) Co., Ltd
Dry Eye
Evaluation of the Efficacy and Safety of DM934 Versus Théalose on Eye Dryness
This study is a multicentric, comparative, randomized, investigator-blinded, parallel group study to demonstrate the non-inferiority of DM934 in comparison with Théalose in terms of cornea and conjunctiva staining (Oxford score)…
- Trial name
- NCT06245421
- Testing
- DM934, Théalose
- Where
- 5 sites in France, Poland and 2 more
- Volunteers
- 85 people
- Sponsor
- Horus Pharma
Dry Eye, Dry Eye Syndromes
Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients
In patients with moderate to severe dry eye syndrome, the test drug (HA 0.15% eye drop) or the control drug (cyclosporin 0.05% eye drop) is administered for 12 weeks, and the corneal staining of each group would be evaluated.
- Trial name
- NCT04127851
- Testing
- TJO-018 (HA 0.15%), Cyclosporine Ophthalmic Emulsion 0.05% standard therapy (CMC 0.5% add), TJO-018 (HA 0.15%) + Cyclosporine Ophthalmic Emulsion 0.05%
- Where
- South Korea
- Volunteers
- 438 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Dry Eye Disease
A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease
The objective of the study is to assess the safety, efficacy, optimum dosage, and dosing regimen of K-161 in adult subjects with moderate to severe dry eye disease.
- Trial name
- NCT04084483
- Testing
- K-161
- Where
- 4 sites in United States
- Volunteers
- 238 people
- Sponsor
- Kowa Research Institute, Inc.
Keratoconjunctivitis Sicca
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS).
- Trial name
- NCT00349466
- Testing
- CF101
- Where
- 3 sites in Israel
- Volunteers
- 80 people
- Sponsor
- Can-Fite BioPharma
Sjögren's Syndrome (SS)
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Primary Objective: To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state Secondary Objectives: 1.
- Trial name
- NCT06245408
- Testing
- Dazodalibep
- Where
- 194 sites in United States, Argentina and 24 more
- Volunteers
- 434 people
- Sponsor
- Amgen
Dry Eye
A Study Evaluating the Efficacy and Safety on Moderate to Severe Dry Eye
The purpose of this study is to compare the efficacy and safety of HBM9036 Ophthalmic Solution versus placebo in the treatment of dry eye
- Trial name
- NCT04092907
- Testing
- HBM9036 0.25% Ophthalmic Solution
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.